Drugs / AstraZeneca
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05387317 | Apr 2024 → Jan 2025 | COVID-19 | Murdoch Childrens Research Institute | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AstraZeneca | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05387317 ↗ |
| Known as | ChAdOx1 nCoV-19 | “ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein” NCT05387317 ↗ |